Patient Enrollment Begins for Australian Trial

May 11, 2020

Patient Enrollment Begins for Australian Trial

Mesoblast, a Melbourne-based biotech company, began enrolling up to 300 patients for a randomized, controlled study of its stem cell therapy remestemcel-L for the treatment of COVID-19. Over 20 hospitals will participate in the study, which is anticipated to last 3-4 months. Yourway is equipped to handle and transport sensitive clinical trial materials, including cell and gene therapies.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Schedule a Meeting

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Schedule a Meeting

Media

Articles

Keeping trials on track: Prioritizing communication in decentralized trials

Open chat

Hello! How can I help you?